09:49 , Aug 19, 2019 |  BC Extra  |  Financial News

Medicxi's returns keep flowing as Celgene's Inrebic approval delivers milestone

Friday's approval of myelofibrosis drug Inrebic fedratinib added to the windfall European venture firm Medicxi has realized from its relatively modest October 2017 investment in Impact Biomedicines Inc., likely returning more total cash than Medicxi...
20:31 , Aug 16, 2019 |  BC Extra  |  Company News

Celgene’s myelofibrosis approval sets up key launch for BMS

FDA's approval of potential blockbuster Inrebic fedratinib from Celgene sets up a key launch for BMS in myelofibrosis, an indication for which only one other drug is marketed in the U.S. The agency's decision also...
02:02 , Aug 10, 2019 |  BioCentury  |  Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
01:12 , Aug 10, 2019 |  BC Extra  |  Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

John Johnson has resigned as CEO of Melinta Therapeutics Inc. (NASDAQ:MLNT). He will stay with the antibiotics company during the search for his successor. David Gill, a board member, was named chairman, replacing Kevin Ferro,...
19:30 , Aug 7, 2019 |  BC Extra  |  Financial News

VCs recapitalize Cleave around next-gen molecule

Seven of the 10 investors in Cleave Therapeutics' existing syndicate have agreed to recapitalize the company with a new $12 million round, with which Cleave will test a second-generation cancer compound following a toxicity snag...
23:54 , Jul 26, 2019 |  BioCentury  |  Product Development

Takeda's deals paint a picture of a turnaround in action

With a spate of new and expanded deals this year, Takeda is not letting its $62 billion dollar takeout of Shire slow its transformation from a traditional small molecule company to a home for edgier,...
00:48 , Jul 26, 2019 |  BC Innovations  |  Product Development

Institute for Protein Design's de novo revolution

Seattle's Institute for Protein Design is growing an army of spinouts that build proteins from the ground up. With applications ranging from multivalent vaccines and synthetic cytokines to precision cell therapies, these companies could put...
22:27 , Jul 25, 2019 |  BC Extra  |  Clinical News

BMS’s strong 2Q outshines mixed Opdivo data in 1L NSCLC

Investors shrugged off mixed data for Opdivo in first-line lung cancer as Bristol-Myers climbed $2.17 to $45.40 on Thursday on 2Q19 earnings that beat the Street's expectations. Bristol-Myers Squibb Co. (NYSE:BMY) reported postmarket data Wednesday...
01:01 , Jul 24, 2019 |  BC Extra  |  Company News

New flexibility and a new Celgene deal for Jounce

With BMS's acquisition of Celgene nearly complete, the big biotech and Jounce ended an immuno-oncology option deal on Tuesday, giving Jounce control over programs that would have overlapped with BMS's pipeline. But the companies will...
19:24 , Jul 19, 2019 |  BC Extra  |  Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

Amgen, Allergan launch pair of biosimilars  Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) launched Mvasi bevacizumab-awwb and Kanjinti trastuzumab-anns in the U.S.; they are the first biosimilars of Avastin bevacizumab and Herceptin trastuzumab available in...